KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Revenue (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Revenue for 16 consecutive years, with $451.8 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 51.6% to $451.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 billion through Dec 2025, up 37.55% year-over-year, with the annual reading at $1.4 billion for FY2025, 37.55% up from the prior year.
  • Revenue for Q4 2025 was $451.8 million at Halozyme Therapeutics, up from $354.3 million in the prior quarter.
  • The five-year high for Revenue was $451.8 million in Q4 2025, with the low at $89.0 million in Q1 2021.
  • Average Revenue over 5 years is $217.2 million, with a median of $212.5 million recorded in 2022.
  • Peak annual rise in Revenue hit 251.12% in 2021, while the deepest fall reached 16.19% in 2021.
  • Over 5 years, Revenue stood at $102.0 million in 2021, then skyrocketed by 77.93% to $181.5 million in 2022, then grew by 26.75% to $230.0 million in 2023, then rose by 29.55% to $298.0 million in 2024, then skyrocketed by 51.6% to $451.8 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $451.8 million, $354.3 million, and $325.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.